Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Media coverage

• Title	Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
  Media name/outlet	PipelineReview
  Country/Territory	Spain
  Date	22/11/22
  URL	https://pipelinereview.com/index.php/2022112282106/DNA-RNA-and-Cells/Caribou-Biosciences-Announces-FDA-Clearance-of-IND-Application-for-CB-011-an-Allogeneic-Anti-BCMA-CAR-T-Cell-Therapy-for-the-Treatment-of-Relapsed-or-Refractory-Multipl.html
  Persons	Sundar Jagannath